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The process by which  B  lymphocytes switch  from synthesis of IgM  to other 
isotypes has been characterized on both the cellular and molecular level (1,  2). 
However, the signals that induce isotype switching and the activation state of the 
responding B  cell are not well understood.  A  T  cell-derived factor (originally 
termed B  cell differentiation factor ~  [BCDF3,]) enhances IgG1  secretion from 
LPS-stimulated B cells (3, 4), and suppresses LPS-induced IgG3 production (5). 
Some sources of this lymphokine are capable of inducing IgG secretion in the 
absence of LPS (6), suggesting that  B  cells activated by stimuli other than  LPS 
are sensitive to the actions of BCDF3,. 
A  T  cell-derived lymphokine called B cell stimulatory factor (BSF-1) induces 
responsiveness to anti-Ig antibodies (7), and increases Ia expression on resting B 
cells (8, 9). Recent evidence (10) suggests that BSF-1 is identical to BCDF3,. BSF- 
1 appears to act at an early stage of anti-Ig stimulation, since cells treated with 
anti-Ig alone rapidly lose responsiveness to this lymphokine (1 1). This contrasts 
with  studies  on  BCDF3',  which  indicated  that  it  was  most  effective on  B  cells 
previously stimulated  by LPS (5).  These data  imply that  anti-Ig,  but not  LPS, 
renders  B  cells  insensitive  to  BSF-1.  In  experiments  reported  here,  B  cells 
cultured with anti-Ig (anti-Ig blasts) were found to secrete high levels of IgG1  in 
response  to a  supernatant  containing a  mixture of lymphokines;  this  response 
was blocked by monoclonal anti-BSF-1. 
Materials and Methods 
Mice.  BALB/c and C57BL/6 mice were obtained from Cumberland Farms, Clinton 
TN, and used at 6-12 wk of age. 
Reagents.  Affinity-purified antibodies of RIA were obtained from Jackson  Immuno- 
research, Avondale, PA (goat anti-mouse lgM +  IgG, and anti-# chain and anti-'r chain), 
and from Southern Biotechnology Associates,  Birmingham, AL (goat anti-IgG1, -IgG3, 
-IgG2a, -IgG2b, and goat anti-x). Myeloma standards were obtained from Litton Bionetics, 
Charleston, SC (MOPC 141, MOPC 21, J606, and MOPC 195). Monoclonal rat anti-BSF- 
BSFI  (12) was generously provided by Dr.  W.  E.  Paul  (National  Institutes of Health, 
Bethesda, MD), and a control rat monoclonal (anti-mouse ~, chain) was provided by Dr. 
E.  Vitetta. Radiochemicals were obtained from New England Nuclear, Boston, MA.  S. 
typhosa LPS was purchased from Difco Laboratories, Detroit, MI. 
Preparation  of B  Cell Blasts.  Goat  anti-mouse  Ig  or  anti-#  chain  antibodies  were 
conjugated to cyanogen bromide-activated Sepharose (Sigma Chemical Co.,  St.  Louis, 
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MO) at a ratio of 1 mg protein per 1 ml swollen gel. B cells (40 ml at 106 cells/ml) were 
added to a 75 cm  2 flask (Falcon Labware, Oxnard, CA) with 80 ttl of packed beads (2/sg 
protein per milliliter final concentration) and  incubated for 24-48  h.  Cells  and beads 
were then removed and centrifuged; the pellet was resuspended in RPMI-1640, layered 
over Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, N  J), and centrifuged for 10 
min at 400 g.  The cells  were collected from the interface and washed twice.  In some 
experiments, anti-Ig blasts and/or B cells were fractionated on Percoll (Sigma  Chemical 
Co.) density gradients. Anti-Ig blasts were essentially all found in the light-density fractions 
(<I.065 g/ml), while >75% of splenic B cells were of density >1.080 g/m]. 
Blasts were also  prepared by culture of B cells with either dextran sulfate (DxS) (50 
#g/ml) or 8-mercaptoguanosine (8-MG)  (0.5 mM).  After 24 or 48 h, cells were washed 
and recultured in microtiter wells. 
T  Cell Supernatants.  Lymphokine-containing supernatant  (SN)  was  obtained  from 
EL-4  cells  as  previously described,  except serum-free conditions  were  used  (6).  This 
preparation contains substantial BCDF3,/BSF-1  activity, as assayed on LPS-treated B cells 
(3) and with anti-Ig-induced B cell proliferation (7). For the experiment shown in Table 
IV, EL-4 SN was passed over a Con A-agarose column. Material that induced proliferation 
of anti-Ig blasts was found in the flow-through, while BSF-1 was retained and eluted with 
0.4 M a-methyl mannoside. 
Cell Culture.  Splenic B cells were prepared by treatment with monoclonal anti-Thy 1 
(kindly provided by Dr. E. S. Vitetta) and baby rabbit complement (Pel-Freeze Biologicals, 
Rogers, AR). B cells and blasts were cultured in 96-well flat-bottomed plates (4 ×  104 cells 
in  200 ~1 RPMI-1640  supplemented with 5%  FCS [Gibco Laboratories, Grand Island, 
NY] and 50 uM 2-ME) for 5 d at 37°C in a humidified atmosphere with 10% CO2. 
Radioimmunoassay.  Culture supernatant was assayed for Ig isotypes by a  solid-phase 
RIA. Polyvinyl chloride plates (Falcon Labware) were coated with an antibody (goat anti- 
IgM +  IgG), which recognized all tested isotypes. After incubation with sample, the plate 
was washed and incubated with ~25I-labeled isotype-specific antibody. The concentration 
of Ig was determined by comparison to standard curves of myeloma Ig with a microcom- 
puter  program  (kindly provided  by  L.  Simpson).  The  isotype-specific antibodies  had 
negligible (<0.1%) crossreactivity with inappropriate heavy chain isotypes or with light 
chains. 
Proliferation Assay.  Anti-Ig blasts  were cultured as above for 48 h, then pulsed with 
[3H]thymidine (1  uCi/well). After 16 h, wells were harvested onto glass fiber filters and 
radioactivity was assessed by liquid scintillation counting. 
Results 
Lymphokine Stimulation of  lgG Secretion  from Anti-Ig Blasts.  Splenic B cells were 
cultured  for  48  h  with  anti-Ig-coated  Sepharose  beads;  after  removal  of the 
beads, culture of these blasts with EL-4 SN resulted in a striking increase in the 
amount of IgG1 secreted into the medium. The pattern of IgG isotypes secreted 
by normal  B  cells and  anti-Ig  blasts  stimulated  with  lymphokines in  EL-4  SN 
alone is shown in Table I. EL-4 SN induced low levels of all  IgG isotypes from 
normal B cells, whereas anti-Ig blasts cultured with EL-4 SN secreted predomi- 
nantly IgG1  (Table I). Similar results were obtained with B cell blasts prepared 
with  anti-Ig  or  anti-#  (Table  I),  and  with  anti-Ig  blasts  separated  on  Percoll 
density gradients (data not shown).  The magnitude of the IgG1  response from 
anti-Ig blasts was markedly higher than that observed with B cells. In six separate 
experiments, anti-Ig blasts secreted an average of 3.9 ug/ml IgG1  in response to 
EL-4 SN, vs.  0.3  ug/ml from splenic B cells. The IgG isotype profile of B cells 
and  anti-Ig blasts  cultured with  LPS is  also  shown  in  Table  I.  Both cell types 
yielded  similar  results:  substantial  IgG3  secretion,  less  IgG1,  and  still  lower 
amounts of IgG2a and IgG2b (Table I). ISAKSON  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
Profile of lgG Isotypes Produced by B Cells and B Cell Blasts 
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Exp.  Cell type  Addition 
lsotype (ng/ml) 
IgG3  lgG1  IgG2a  IgG2b 
1  B Cells 
1  Anti-t~  blasts 
2  B cells 
None  3  1  2  0 
LPS  1,200  458  86  85 
EL-4 SN  22  105  78  II 
None  2  6  2  0 
LPS  632  291  32  55 
EL-4 SN  37  3,883  II  4 
None  0  0  6  1 
LPS  417  303  47  46 
EL-4 SN  73  494  48  57 
Anti-lg blasts  None  5  16  12  7 
LPS  93  314  34  16 
EL-4 SN  25  3,251  63  38 
Blasts  were prepared  as described  in  Materials and  Methods,  and  recultured at  2  ×  105 
cells/ml with  LPS (25 tag/ml) or a  maximally effective  dilution  of EL-4 SN;  B  cells were 
treated similarly without culture with Sepharose. Results presented are the mean of triplicate 
wells. 
TABLE  II 
lgG Isotypes Produced by Other B Cell Blasts 
Pre-incubated with: 
Addition to  Isotype (ng/rnl) 
secondary 
culture  lgG3  lgGl  IgG2a  IgG2b 
No addition (24 h) 
8-MG (1  raM) (24 h) 
None  2  0  0  0 
LPS  1,180  280  24  14 
EL-4 SN  17  283  9  4 
None  3  9  2  1 
LPS  360  116  37  16 
EL-4 SN  15  142  75  29 
DxS(50 gg/ml)(24 h)  None  2  7  0  0 
LPS  875  430  12  11 
EL-4 SN  35  282  16  3 
DxS (48 h)  None  0  0  0  0 
LPS  2,240  519  2  7 
EL-4 SN  59  615  2  0 
B  cells were cultured for 24 or  48 h  at  108 cells/ml with the 
washed and cultured in microtiter plates at 2  ×  105 cells/ml for 
indicated additions, 
5d. 
IgG Response of Other B Cell Blasts.  The heightened IgG1  response of anti-Ig 
blasts  could  be  typical  of  B  cell  blasts  produced  in  vitro.  To  examine  this 
possibility,  B  cells were cultured  for  1-2  d  with DxS  or  8-MG,  two chemicals 
that induce B cell blasts (13,  14). The results of a representative experiment are 
shown in Table II. The viability of cells cultured for 48 h with 8-MG was poor, 
so only data for 24-h 8-MG blasts is shown. In contrast to results obtained with 
anti-Ig  blasts,  the  isotype  profile  with  both  8-MG  blasts  and  DxS  blasts  were 
similar to that obtained with normal B cells, except that the DxS blasts secreted 
very little IgG2a or IgG2b in response to either stimulus. 
Anti-BSF-1 Inhibits the IgG1 Response of Anti-Ig Blasts.  An mAb against BSF-1 
was previously shown  (12)  to inhibit  BCDF3,  activity.  Preliminary experiments 306  ISAKSON  BRIEF  DEFINITIVE  REPORT 
TABLE  III 
Effect of Monoclonal Anti-BSF-1 on Responses of Anti-lg Blasts 
Exp.  Addition 
IgGl (ng/ml)  IgM (ng/nd) 
Control  Anti-BSF- 1  Control  Anti-BSF-I 
1  None  <10  <10  700  800 
EL-4 SN  794  16  7,700  6,600 
2  None  <10  <10  100  300 
EL-4 SN  2,022  116  20,500  23,100 
*  B  cells  were  incubated  for  two  days  with  GAMlg-Sepharose  (Exp.  1)  or  GAMu 
Sepharose (Exp.  2), then re-cultured for five days in the presence or absence of a 
suboptimal concentration of EL-4 SN. Either a control antibody or 11BI 1 anti-BSF- 
1 were added at a  1:4000 dilution. 
TABLE  IV 
Proliferative Responses of Anti-Ig Blasts 
Exp.  Addition 
[~H]Tbymidine incorporation 
(cpm x  10  -s) 
Control  Anti-BSF-1 
None  2.6  2.9 
LPS  27.0  27.2 
EL-4 SN  76.7  67.4 
None  2.9  1.3 
EL-4 SN  36.6  32.0 
EL-4 SN (Con A  eluate)*  3.2  1.4 
Anti-lg blasts were cultured for 2 d, then assayed for incorporation of [3H]thymidine. 
*  EL-4  SN  was passed  over  a  Con  A-agarose  colunm  and  eluted  as  described  in 
Materials and Methods; a dilution giving half-maximal BSF-I  activity was added. 
determined  optimal  concentrations  of antibody required  to neutralize  BCDF? 
activity on LPS-treated B cells (data not shown). When anti-BSF-1  was included 
in cultures of anti-Ig blasts, the IgG1 response to EL-4 SN was suppressed (Table 
III). The same wells were also assayed for polyclonal IgM secretion  induced by 
EL-4 SN; anti-BSF-1  had little or no effect on this response,  indicating that the 
inhibition of IgG1  secretion was isotype specific. 
Proliferative  Responses  of Anti-lg  Blasts.  It  was  possible  that  anti-lg  blasts 
prepared here proliferated  in response to BSF-1,  in contrast to previous results 
(11,  15).  This was exanfined by determining the effect  of anti-BSF-1  on prolif- 
eration  in  response to EL-4 SN,  and by testing a partially purified preparation 
of BSF-1  on anti-Ig blasts (Table  IV). Crude EL-4 SN caused marked prolifera- 
tion of anti-Ig blasts, in agreement with the results of Muller et al. (15); addition 
of  anti-BSF-1  had  little  effect  on  this  response,  suggesting  that  it  was  not 
dependent on BSF-1  in the EL-4 SN. The lymphokine that is mitogenic for anti- 
Ig blasts does not bind to Con A-agarose (L. Simpson and P. Isakson, unpublished 
data), whereas BSF-1  is bound. As shown in Table IV, the eluate from a Con A- 
agarose column had little mitogenic activity on anti-Ig blasts; this same fraction 
had substantial BSF-1  activity in a costimulator assay (7), but did not induce IgG 
secretion from anti-Ig blasts (data not shown). ISAKSON  BRIEF  DEFINITIVE REPORT  307 
Discussion 
The T  cell-derived lymphokine BSF-1 increases the number of resting B cells 
that  enter  S  in  response  to  anti-Ig  (7,  16).  Anti-Ig-pretreated  cells  are  not 
sensitive to BSF-1  (17), suggesting that  BSF-1 acts primarily during early stages 
of entry into cell cycle. In contrast, studies (5) with BCDF'y, which is apparently 
identical  to BSF-1, showed that  it was most effective with  previously activated 
cells. Two important  points can be made based on experiments reported here. 
First,  B  cells  treated  with  anti-Ig  secrete  high  levels  of IgG1  in  response  to 
lymphokines present in EL-4 SN. Second, anti-Ig blasts appear to be capable of 
responding to a  lymphokine with the antigenic properties of BSF-1. The latter 
conclusion  is  based  on  the  ability  of anti-BSF-1  to  specifically  inhibit  IgG1 
secretion, and provides strong evidence that anti-Ig blasts are responsive to BSF- 
1.  Thus,  treatment  with anti-Ig  may render  B cells insensitive to one effect of 
BSF-1 (proliferation enhancement) but not another (isotype switching). 
The experiment shown in Table IV suggests that BSF-1 alone is incapable of 
either  maintaining  proliferation  of anti-Ig  blasts  or  inducing  IgG1  secretion. 
Thus,  another  lymphokine  capable  of  maintaining  B  cell  proliferation  and 
inducing  Ig secretion appears to act in concert with BSF-1  on anti-Ig blasts.  It 
should  be  noted  that  complete  inhibition  of  IgG1  secretion  was  not  always 
obtained with anti-BSF-1 (cf. Exp. 2, Table III). A definitive explanation for this 
finding  will  require  the  use of purified  lymphokines.  The  finding  that  B  cell 
blasts produced by 8-MG or DxS do not show heightened IgG1 responses (Table 
II) could reflect low responsiveness to either BSF-1 or to another lymphokine. 
In conclusion, anti-Ig blasts can be induced to switch isotypes by T cell-derived 
lymphokines alone. Since anti-Ig blasts do not divide or secrete Ig in the absence 
of further stimulation,  they may provide a  useful model for elucidating signals 
for growth and for stimulation of IgM vs. IgG secretion. 
Summary 
We have determined  whether  B cells previously activated by anti-Ig  (anti-Ig 
blasts) are responsive to lymphokines that  induce isotype switching.  Culture  of 
anti-Ig blasts with a mixture of lymphokines, including BSF-1, resulted in marked 
secretion of IgM and  IgG1, but not other IgG isotypes. The  IgG1  response of 
anti-Ig blasts to lymphokines was 13-fold greater than was observed with splenic 
B cells. B cell blasts induced by 8-mercaptoguanosine or dextran sulfate did not 
secrete high levels of any IgG isotype in response to lymphokines alone. An mAb 
against  BSF-1  suppressed the  IgG1  response of anti-Ig blasts, but not the  IgM 
response to lymphokines. These data suggest that anti-Ig-treated B cells respond 
to at least one of the effects of BSF-1. 
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